scholarly journals Corrigendum to ‘High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality’ [ Eur J Heart Fail 2021;23:919–932]

2021 ◽  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Transferrin Receptor ◽  
Strong Predictor ◽  
Soluble Transferrin Receptor ◽  
Patients With Heart Failure

scholarly journals Effect of Fortification with Multiple Micronutrient Powder on the Prevention and Treatment of Iron Deficiency and Anaemia in Brazilian Children: A Randomized Clinical Trial

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2160
Author(s):  
Malaine Morais Alves Machado ◽  
Mirella de Paiva Lopes ◽  
Raquel Machado Schincaglia ◽  
Paulo Sérgio Sucasas da Costa ◽  
Alexandre Siqueira Guedes Coelho ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Serum Ferritin ◽  
Transferrin Receptor ◽  
Ferrous Sulfate ◽  
Soluble Transferrin Receptor ◽  
Standard Drug ◽  
Micronutrient Powder ◽  
Prevention And Treatment ◽  
Multiple Micronutrient ◽  
Multiple Micronutrient Powder

Fortification with multiple micronutrient powder has been proposed as a public health intervention able to reduce micronutrient deficiencies in children. Our objective was to compare the effectiveness of fortification with multiple micronutrient powder with drug supplementation in the prevention and treatment of iron deficiency and anaemia. This was a cluster trial with anemic and non-anaemic children between six and 42 months old, in randomization data. Non anaemic children received fortification with multiple micronutrient powder or standard drug supplementation of ferrous sulfate associated with folic acid in a prevention dose. Anaemic children who were randomized to receive multiple micronutrient powder also received the recommended iron complementation for anaemia treatment. A total of 162 children were evaluated. The prevalence of anaemia decreased from 13.58 to 1.85%. Iron deficiency decreased from 21.74% to 7.89% (by serum ferritin) and iron deficiency decreased from 66.81 to 38.27% (by soluble transferrin receptor). No difference was identified between interventions for hemoglobin (p = 0.142), serum ferritin (p = 0.288), and soluble transferrin receptor (p = 0.156). Fortification with multiple micronutrient powder was effective in preventing iron deficiency and anaemia in children aged six to 48 months. In anaemic children; it was necessary to supplement the dose of multiple micronutrient powder with ferrous sulfate.

The value of soluble transferrin receptor and Tfr-Ferritin index in the differential diagnosis of iron deficiency anemia

2009 ◽  
Vol 42 (4-5) ◽  
pp. 343-344
Author(s):  
Tulay Keskin ◽  
Ozlem Hurmeydan ◽  
Yalcin Onder ◽  
Lale Dagdelen ◽  
Nazli Caner ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Transferrin Receptor ◽  
Deficiency Anemia ◽  
Soluble Transferrin Receptor

scholarly journals Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners

2016 ◽  
Vol 17 (3) ◽  
pp. 183-201 ◽  
Author(s):  
Marcin Drozd ◽  
Ewa A. Jankowska ◽  
Waldemar Banasiak ◽  
Piotr Ponikowski
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Iron Therapy ◽  
Patients With Heart Failure

scholarly journals Expert consensus regarding treatment of iron deficiency in stable and decompensated patients with heart failure

Kardiologiia ◽  
2021 ◽  
Vol 61 (4) ◽  
pp. 73-78
Author(s):  
Yu. V. Mareev ◽  
S. R. Gilarevsky ◽  
Yu. L. Begrambekova ◽  
Yu. M. Lopatin ◽  
A. A. Garganeeva ◽  
...  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ferric Carboxymaltose ◽  
Ventricular Ejection Fraction ◽  
Patients With Heart Failure ◽  
High Prevalence ◽  
Acute Decompensation

In recent years there has been significant interest in treating iron deficiency (ID) in patients with heart failure (HF) due to its high prevalence and detrimental effects in this population. As stated in the 2020 Russain HF guidelines, Intravenous ferric carboxymaltose remains the only proven therapy for ID.This document was prompted by the results from the recent AFFIRM-AHF trial which demonstrates that treatment of ID after acute HF decompensation reduces the risk of future decompensations. Experts have concluded that in HF patients with acute decompensation, a left ventricular ejection fraction of < 50% and ID, Intravenous ferric carboxymaltose reduces future HF hospitalisations. Patients with stable HF may also benefit from treatment of ID to improve quality of life and alleviate symptoms.  It is, therefore, reasonable to screen for and treat ID in patients with HF.

Use of soluble transferrin receptor (TfR) for the diagnosis of iron deficiency anemia (IDA) in cirrhotic patients

2002 ◽  
Vol 36 ◽  
pp. 208
Author(s):  
Alicia Rosso ◽  
Adrian Gadano ◽  
Pablo Rendo ◽  
Jorge Arbelbide ◽  
Eliseo Gonzalez ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Transferrin Receptor ◽  
Deficiency Anemia ◽  
Soluble Transferrin Receptor ◽  
Cirrhotic Patients
Sign in / Sign up

Export Citation Format

Share Document